logo

Materials published with permission of the copyright holder

RU / EN

Moscow, November 15, 2024, 12.00-15.00

XIII International symposium
3P-medicine concept in treatment and monitoring

2024
2023
2022
2021
2020
2019
2018
2017
2016

About symposium

Dear colleagues, we invite you to take part in the XIII International Webinar: «Controversies in Glaucoma: 3P-medicine concept in treatment and monitoring», which will be held on November, 15, 2024.

Glaucoma, being one of the leading causes of blindness in the world, requires special attention from the medical community. It is evident that we need a shift to “predictive, preventive and personalised medicine” as a new philosophy covering both “health care” and “disease care”, promoting an integrated approach combining advantages of individual biomedical fields and technologies and consolidating a multi-professional collaboration. The application of the 3P-medicine concept is the key to solving glaucoma problems.

This year symposium will be marked by the participation of international experts from Germany (O. Golubnitschaja), China (G. Wang, H.Chen), the USA (B. Xu) and Russia (D.S. Maltsev, N.I. Kurysheva, S.G. Kapkova). The project is authored and coordinated by Professor Natalya Kurysheva.

Download the program (PDF)

Download the program (PDF)

Reports

3-PM innovations: what are the perspectives?
speaker
Olga Golubnitschaja
Germany

3-PM innovations: what are the perspectives?

Prof. Dr. Olga Golubnitschaja, as President of the European Association for Predictive, Preventive and Personalised Medicine (EPMA), will discuss innovations and perspectives in 3P medicine in her lecture. Over the past 15 years, EPMA has implemented advanced population screening programmes, personalised medical services such as individualised prediction and prognosis, cost-effective prevention, personalised treatments tailored to the person.

Multi-dimensional imaging model for screening of primary open angle glaucoma
speaker
Geng Wang
China

Multi-dimensional imaging model for screening of primary open angle glaucoma

Geng Wang et al. have developed a multi-dimensional imaging model specifically designed to detect primary open-angle glaucoma (POAG) using a convolutional neural network algorithm. The report will present the results from testing the model and explore its clinical applications for detecting POAG, particularly in patients with myopia.

Personalized confidence level of artificial intelligence in predicting retinal diseases
speaker
Haoyu Chen
China

Personalized confidence level of artificial intelligence in predicting retinal diseases

Development of artificial intelligence (AI) technique has allowed for prediction of retinal diseases. Haoyu Chen et al. developed a foundation model with uncertainty estimation (FMUE) to detect 11 retinal conditions. This lecture will present the results of FMUE testing, its comparison with two state-of-the-art algorithms, RETFound and UIOS.

Long-Term Risk and Prediction of Progression in Primary Angle Closure Suspect
speaker
Benjamin Yi Xing Xu
USA

Long-Term Risk and Prediction of Progression in Primary Angle Closure Suspect

In this lecture, Dr. Xu will discuss recent advances in early detection and prevention of primary angle closure glaucoma (PACG). The results of recent scientific studies combining OCT imaging and artificial intelligence to develop novel angle closure detection and risk stratification methods will be presented.

PPP-medicine concepts to glaucoma treatment and monitoring
speaker
Natalia I. Kurysheva
Russia

PPP-medicine concepts to glaucoma treatment and monitoring

Currently, the research vector is aimed at developing artificial intelligence algorithms to predict the rate of glaucoma progression. Based on models of neural networks, it is possible to individually predict the course of the disease and choose algorithms for its treatment. The report provides data from our own research on mathematical modeling of a personalized approach to the treatment and monitoring of patients with various forms of glaucoma.

OCT biomarkers for personalized treatment of AMD patients
speaker
Dmitrii Maltsev
Russia

OCT biomarkers for personalized treatment of AMD patients

Currently, the most modern OCT devices provide wide-field visualization of the posterior segment, analysis of retinal microcirculation and morphometry of the anterior segment with high resolution. This leads to the discovery of a large number of biomarkers that require determining their role in clinical decision-making for treatment. Professor Maltsev will discuss the possibilities of personalized treatment options for patients with neovascular age-related macular degeneration using novel biomarkers.

Neuroprotection from the point of 3-PM
speaker
Natalia I. Kurysheva
Russia

Neuroprotection from the point of 3-PM

Neuroprotective treatment of glaucoma is aimed at preserving visual functions in conditions of normalized ophthalmotonus and involves management of various links in the pathogenesis of glaucoma opticoneuropathy. Based on the existence of various glaucoma phenotypes and individual characteristics of the course of the glaucoma process, the choice of neuroprotective treatment is also individual, based on the concept of 3P medicine. The report provides clinical examples of such approaches.

A personalized approach to the treatment and monitoring of patients with AMD and glaucoma
speaker
Kapkova Svetlana
Russia

A personalized approach to the treatment and monitoring of patients with AMD and glaucoma

The combination of glaucoma with AMD significantly worsens the course of both diseases. There are many similarities in the pathogenesis of glaucoma and AMD, on the other hand, the risk of side effects in standard treatment in patients with combined pathology is significantly higher. Therefore, an individual approach is especially indicated for this category of patients. The report presents the results of our own research on predicting the effectiveness of anti-VEGF therapy, taking into account this approach.

Discussion
speaker
Russia

Discussion

Reporter

Olga Golubnitschaja
Olga Golubnitschaja
Germany

Professor, the head of the world first Predictive, Preventive Personalised Medicine (3PM) unit at the Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany. Dr. Golubnitschaja is the author of more than 400 internationally peer-reviewed publications in the innovative field of predictive, preventive and personalised medicine (3PM) with the main research focuses on sub-optimal health conditions, pre- and perinatal diagnostics, diagnostics of cardiovascular disease and neurodegenerative pathologies, predictive diagnostics in cancer and diabetes. Was awarded Highest Prize in Medicine and Eiselsberg-Prize in Austria, National & International Fellowship of the Alexander von Humboldt-Foundation, Springer-Nature Award, EMA Award. Cumulative Scopus h-index is 61; Citations indexed by Google Scholar in 2024: >800.<br>Since 2021 she is the President of the “European Association for Predictive, Preventive & Personalised Medicine” (EPMA, Brussels) networking 56 countries worldwide. She is Editor-in-Chief of the EPMA J. (actual Scopus CiteScore 12.5) and Editor-in-Chief of the Book Series “Advances in Predictive, Preventive & Personalised Medicine”. Dr. Golubnitschaja is the European Representative in the EDR-Network at the National Institutes of Health USA. Dr. Golubnitschaja acts as a regular reviewer in over 50 clinical and scientific journals and as a grant reviewer of inter/national funding bodies in European and other countries.<br>Dr. Golubnitschaja is an evaluation expert at the European Commission. In years 2010-2013 she was involved in creating the PPPM related contents of the European Programme “Horizon 2020”. Dr. Golubnitschaja as the Vice-Chair of the Habilitation Committee in years 2019-2023 was responsible for all medical specialisations at the Medical Faculty, University of Bonn, Germany. Dr. Golubnitschaja acts as Vice-Chair of the Evaluation Panel for Marie Curie Mobility Actions at the European Commission in Brussels. Dr. Golubnitschaja is a shareholder of the consulting company 3PMedicon, Austria specialised in 3PM.

Geng Wang
Geng Wang
China

Geng Wang, PhD, Chief Physician of the Department of Ophthalmology at Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou, China.<br>He has been practicing ophthalmology for more than 16 years, studied at the Chinese University of Hong Kong and the Ruhr University in Germany. Currently, he is a member of the Chinese Medical Association, an ophthalmology expert at the Chinese Geriatric Society, a member of the Standing Committee on Optometry Education, a member of the Provincial Committee on Health Economics and Health Promotion of Guangdong Province and the Committee on Medical Communications.<br>Dr. Wang has participated in many national and international professional ophthalmology conferences. In 2005, he passed the exam of the International Council of Ophthalmology (ICO), taking first place in the ranking of China, and later was invited to the International Council of Ophthalmology (ICO) as an observer. Geng Wang, as part of the Chinese expert group, traveled to Burundi (East Africa) to carry out a mission to provide ophthalmological medical care to the population.

Haoyu Chen
Haoyu Chen
China

Professor, Associate Director (research and education), physician-scientist working at Joint Shantou International Eye Center, Shantou University & the Chinese University of Hong Kong, China. As a physician, he performs more than 2000 operations and 5000 outpatient consultations annually. He takes care of ocular trauma and retina service, clinical research, basic research, undergraduate education, and post-graduate programs at JSIEC. Prof. Chen is an established ophthalmic researcher internationally known in molecular medicine, ophthalmic imaging, computer software, with over than 200 original articles and H-index 37 (Scopus).<br>Prof. Chen also served as an associate editor for BMC Ophthalmology and editorial board member for International Ophthalmology. He received the Asia Pacific Academy of Ophthalmology Achievement Award, the Outstanding Ophthalmologist Award of the Chinese Ophthalmologist Association, Publons Peer Review Awards.

Benjamin Yi Xing Xu
Benjamin Yi Xing Xu
USA

Assistant Professor Of Clinical Ophthalmology, Director of Inpatient Ophthalmology Service of Keck Hospital of USC. Dr. Xu’s primary research interest is preventing vision loss and blindness in patients at risk for angle closure glaucoma (ACG), a common type of glaucoma. His research focuses on studying the pathophysiology of ACG and improving the care of angle closure patients. Dr. Xu also uses advanced anterior segment imaging modalities including anterior segment optical coherence tomography (AS-OCT) and ultrasound biomicroscopy (UBM) to study the physiological and biomechanical properties of intraocular structures and aqueous outflow pathways. Finally, Dr. Xu works on designing biomedical devices to assess the function of anterior segment structures, such as the iris and trabecular meshwork. Dr. Xu has coauthored more than 30 peer-reviewed publications and a book on ocular imaging in glaucoma. He has also received numerous research awards, including those from the National Institutes of Health, American Glaucoma Society and Fight for Sight.

Dmitrii Maltsev
Dmitrii Maltsev
Russia

Dr. of Medical Sciences, Professor of the Department of Ophthalmology, S.M. Kirov Military Medical Academy, Russian Federation. Professor Maltsev is an expert in the diagnostics and treatment of retinal diseases. The author of more than 200 scientific papers in leading scientific journals, including the journals "Russian Annals of Ophthalmology", "Retina", "Eye" and many others. He has a patent of the Russian Federation for the invention. In his doctoral dissertation, he explored the possibilities of artificial intelligence and machine learning in the diagnosis of retinal diseases. Prof. Maltsev is one of the authors of the monograph "Multimodal optical coherence tomography", labeled as a bestseller among ophthalmological publications in 2023. Prof. Maltsev is annually invited as a speaker at Russian and international ophthalmological conferences, such as the International Congress on OCT and OCT Angiography ICOOR. Creator of ophthalmology courses.

Natalia I. Kurysheva
Natalia I. Kurysheva
Russia

Dr. of Medical Sciences, Head of the Department of Eye Diseases of the Federal Medical and Biological University of Innovations and Continuing Education of the FMBA of Russia; Professor of the Department of Ophthalmology of the APO of the FSBI FNCC of the FMBA of Russia; Head of the Consultative and Diagnostic Department of the Center of Ophthalmology of the FMBA of Russia; a member of the European Glaucoma Society and the American Academy of Ophthalmology; honorary member of the Italian Glaucoma Society; scientific supervisor and coordinator of the Federal Target Group Programs «Glaucoma Opticoneuropathy». Natalia is a representative of Russian Ophthalmology in the European Association of Predictive, Preventive and Personalized Medicine. The research interests: etiology, pathogenesis, laser and surgical treatment of glaucoma, neuroprotection, angle-closure, normotensive and pseudoexfoliative glaucoma, retinal diseases. For the last 10 years, she has been studying new methods of optic nerve and retina visualization in glaucoma, the progression of the disease, and ocular blood flow and the personalized treatment of the primary angle clouser. Author of more than 300 scientific papers, including 50 papers in international peer-reviewed journals, 10 monographs on the diagnosis and treatment of glaucoma and ocular blood flow, as well as 10 patents for inventions. Member of the editorial board of the National Journal of Glaucoma (Russia) and Ophthalmology Journal (Russia), a reviewer of the British Journal of Ophthalmology (BJO), Bulletin of Ophthalmology and other prominent international journals. She was awarded by the Ministry of Education of the Russian Federation for scientific research on topical issues of fundamental and applied science in the field of education, achievements in the training of highly qualified specialists, for the introduction of new forms and methods of teaching in the educational process. The author of two recent monographs: COVID-19 and visual organ damage, 2021, and Dry age-related macular degenerations, 2021, a member of International Optical Circulation Society (IOCS).

Kapkova Svetlana
Kapkova Svetlana
Russia

Ph.D. of Medical Sciences, docent of the Department of Eye Diseases of the Federal Medical and Biological University of Innovations and Continuing Education of the FMBA of Russia, Head of the Ophthalmology Department with the Office of Laser Surgery of the A.I. Burnazyan State Medical Research Center of the FMBA of Russia. Performs a wide range of ophthalmic operations daily, including glaucoma surgery, reconstructive surgery of the anterior segment of the eye, refractive surgery. She is actively engaged in scientific work in the development of new approaches to the treatment of glaucoma, as well as combined eye pathology.

Program

November 15, 2024
12.00 - 12.05
Welcoming speech and introductions (Greeting: akad. V.A.Chereshnev, professor B. E. Malyugin, professor V.N. Trubilin).
12.05 - 12.20
speaker

Prof. Dr. Olga Golubnitschaja, as President of the European Association for Predictive, Preventive and Personalised Medicine (EPMA), will discuss innovations and perspectives in 3P medicine in her lecture. Over the past 15 years, EPMA has implemented advanced population screening programmes, personalised medical services such as individualised prediction and prognosis, cost-effective prevention, personalised treatments tailored to the person.

3-PM innovations: what are the perspectives?

Golubnitschaja O., Germany

Prof. Dr. Olga Golubnitschaja, as President of the European Association for Predictive, Preventive and Personalised Medicine (EPMA), will discuss innovations and perspectives in 3P medicine in her lecture. Over the past 15 years, EPMA has implemented advanced population screening programmes, personalised medical services such as individualised prediction and prognosis, cost-effective prevention, personalised treatments tailored to the person.

12.05 - 12.20
12.20 - 12.40
speaker

Geng Wang et al. have developed a multi-dimensional imaging model specifically designed to detect primary open-angle glaucoma (POAG) using a convolutional neural network algorithm. The report will present the results from testing the model and explore its clinical applications for detecting POAG, particularly in patients with myopia.

Multi-dimensional imaging model for screening of primary open angle glaucoma

G. Wang, China

Geng Wang et al. have developed a multi-dimensional imaging model specifically designed to detect primary open-angle glaucoma (POAG) using a convolutional neural network algorithm. The report will present the results from testing the model and explore its clinical applications for detecting POAG, particularly in patients with myopia.

12.20 - 12.40
12.40 - 13.00
speaker

Development of artificial intelligence (AI) technique has allowed for prediction of retinal diseases. Haoyu Chen et al. developed a foundation model with uncertainty estimation (FMUE) to detect 11 retinal conditions. This lecture will present the results of FMUE testing, its comparison with two state-of-the-art algorithms, RETFound and UIOS.

Personalized confidence level of artificial intelligence in predicting retinal diseases

H. Chen, China

Development of artificial intelligence (AI) technique has allowed for prediction of retinal diseases. Haoyu Chen et al. developed a foundation model with uncertainty estimation (FMUE) to detect 11 retinal conditions. This lecture will present the results of FMUE testing, its comparison with two state-of-the-art algorithms, RETFound and UIOS.

12.40 - 13.00
13.00 - 13.20
speaker

In this lecture, Dr. Xu will discuss recent advances in early detection and prevention of primary angle closure glaucoma (PACG). The results of recent scientific studies combining OCT imaging and artificial intelligence to develop novel angle closure detection and risk stratification methods will be presented.

Long-Term Risk and Prediction of Progression in Primary Angle Closure Suspect

BY Xu, USA

In this lecture, Dr. Xu will discuss recent advances in early detection and prevention of primary angle closure glaucoma (PACG). The results of recent scientific studies combining OCT imaging and artificial intelligence to develop novel angle closure detection and risk stratification methods will be presented.

13.00 - 13.20
13.20 - 13.40
speaker

Currently, the research vector is aimed at developing artificial intelligence algorithms to predict the rate of glaucoma progression. Based on models of neural networks, it is possible to individually predict the course of the disease and choose algorithms for its treatment. The report provides data from our own research on mathematical modeling of a personalized approach to the treatment and monitoring of patients with various forms of glaucoma.

PPP-medicine concepts to glaucoma treatment and monitoring

Kurysheva N., Russia

Currently, the research vector is aimed at developing artificial intelligence algorithms to predict the rate of glaucoma progression. Based on models of neural networks, it is possible to individually predict the course of the disease and choose algorithms for its treatment. The report provides data from our own research on mathematical modeling of a personalized approach to the treatment and monitoring of patients with various forms of glaucoma.

13.20 - 13.40
13.40 - 14.00
speaker

Currently, the most modern OCT devices provide wide-field visualization of the posterior segment, analysis of retinal microcirculation and morphometry of the anterior segment with high resolution. This leads to the discovery of a large number of biomarkers that require determining their role in clinical decision-making for treatment. Professor Maltsev will discuss the possibilities of personalized treatment options for patients with neovascular age-related macular degeneration using novel biomarkers.

OCT biomarkers for personalized treatment of AMD patients

Maltsev D., Russia

Currently, the most modern OCT devices provide wide-field visualization of the posterior segment, analysis of retinal microcirculation and morphometry of the anterior segment with high resolution. This leads to the discovery of a large number of biomarkers that require determining their role in clinical decision-making for treatment. Professor Maltsev will discuss the possibilities of personalized treatment options for patients with neovascular age-related macular degeneration using novel biomarkers.

13.40 - 14.00
14.00 - 14.20
speaker

Neuroprotective treatment of glaucoma is aimed at preserving visual functions in conditions of normalized ophthalmotonus and involves management of various links in the pathogenesis of glaucoma opticoneuropathy. Based on the existence of various glaucoma phenotypes and individual characteristics of the course of the glaucoma process, the choice of neuroprotective treatment is also individual, based on the concept of 3P medicine. The report provides clinical examples of such approaches.

Neuroprotection from the point of 3-PM

Kurysheva N., Russia

Neuroprotective treatment of glaucoma is aimed at preserving visual functions in conditions of normalized ophthalmotonus and involves management of various links in the pathogenesis of glaucoma opticoneuropathy. Based on the existence of various glaucoma phenotypes and individual characteristics of the course of the glaucoma process, the choice of neuroprotective treatment is also individual, based on the concept of 3P medicine. The report provides clinical examples of such approaches.

14.00 - 14.20
14.20 - 14.40
speaker

The combination of glaucoma with AMD significantly worsens the course of both diseases. There are many similarities in the pathogenesis of glaucoma and AMD, on the other hand, the risk of side effects in standard treatment in patients with combined pathology is significantly higher. Therefore, an individual approach is especially indicated for this category of patients. The report presents the results of our own research on predicting the effectiveness of anti-VEGF therapy, taking into account this approach.

A personalized approach to the treatment and monitoring of patients with AMD and glaucoma

Kapkova S., Russia

The combination of glaucoma with AMD significantly worsens the course of both diseases. There are many similarities in the pathogenesis of glaucoma and AMD, on the other hand, the risk of side effects in standard treatment in patients with combined pathology is significantly higher. Therefore, an individual approach is especially indicated for this category of patients. The report presents the results of our own research on predicting the effectiveness of anti-VEGF therapy, taking into account this approach.

14.20 - 14.40
14.40 - 15.00
Discussion and closing remarks
Download the program (PDF)

Download the program (PDF)

Sponsors

Information partners